Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AEROSEB-DEX vs ALA-SCALP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
The combination product contains a corticosteroid (dexamethasone) which suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and a topical antibiotic (usually neomycin or polymyxin B) which inhibits bacterial protein synthesis or disrupts bacterial cell membranes.
ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (Pp IX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), Pp IX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.
Ophthalmic corticosteroid-responsive inflammatory conditions with concurrent bacterial infection or risk of infection,Blepharitis,Conjunctivitis,Keratitis,Iritis,Cyclitis
Treatment of minimally to moderately thick actinic keratoses of the scalp (Grade 1 or 2) in immunocompetent patients,Off-label: other photosensitivity disorders
2 puffs (100 mcg each) intranasally twice daily
Topical application of a 5% solution to the scalp twice daily.
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Not applicable; topical ALA-SCALP is not significantly absorbed systemically. After systemic absorption from photodynamic therapy, terminal half-life is approximately 1 hour due to rapid metabolism.
Dexamethasone is metabolized primarily in the liver via CYP3A4; topical antibiotics (neomycin, polymyxin B) are minimally absorbed and not significantly metabolized.
ALA is metabolized intracellularly via the heme biosynthesis pathway to protoporphyrin IX (Pp IX).
Renal elimination of unchanged drug accounts for 30-40% of the dose; fecal/biliary elimination is 50-60% as metabolites. Less than 10% is excreted unchanged in feces.
Primarily renal elimination of metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion is negligible.
Approximately 85% bound to serum albumin and alpha-1-acid glycoprotein.
Not characterized; systemic levels are negligible after topical administration.
Vd is 3-4 L/kg, indicating extensive tissue distribution with accumulation in liver and kidneys.
Not applicable for topical route. If systemic exposure occurs, Vd is approximately 0.5 L/kg, consistent with distribution into total body water.
Oral: 40-50% due to first-pass metabolism; Topical: 5-10% systemically; IV: 100%.
Topical: Systemic bioavailability is minimal (<1%) due to poor percutaneous absorption and rapid local metabolism.
No adjustment required for any GFR level
No dose adjustment required for renal impairment.
Child-Pugh Class A: no adjustment; Child-Pugh Class B/C: no data available; use with caution
No dose adjustment required for hepatic impairment.
Children 6-11 years: 1 puff (50 mcg) per nostril twice daily; Children ≥12 years: same as adult
Safety and efficacy in pediatric patients have not been established.
No specific dose adjustment; monitor for adrenal suppression and osteoporosis risk with prolonged use
No specific dose adjustment recommended; use with caution due to potential increased sensitivity.
Prolonged use may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision, and posterior subcapsular cataract formation. Prolonged use may suppress the host response and thus increase the hazard of secondary ocular infections. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids.
No FDA black box warning.
Prolonged use may lead to ocular hypertension/glaucoma,Posterior subcapsular cataract formation,Delayed wound healing,Secondary ocular infections (including fungal infections),Corneal/scleral thinning and perforation,Systemic absorption with prolonged use (especially in children),Avoid use in patients with known hypersensitivity to any component
Photosensitivity: avoid exposure to sunlight or bright indoor light (e.g., examination lamps, operating room lamps) for at least 40 hours post-application.,Application site reactions: severe stinging, burning, erythema, and edema may occur.,Use sun-protective measures (e.g., wide-brimmed hat, sunscreen) after treatment.,Do not apply to eyes or mucous membranes.
Epithelial herpes simplex keratitis (dendritic keratitis),Vaccinia, varicella, and other viral infections of the cornea and conjunctiva,Mycobacterial infections of the eye,Fungal diseases of ocular structures,Hypersensitivity to any component of the formulation
Hypersensitivity to aminolevulinic acid or any component of the formulation,Cutaneous photosensitivity at wavelengths of 400-450 nm,Porphyria
No specific food interactions. Avoid grapefruit juice as it may increase systemic exposure to ciclesonide via CYP3A4 inhibition.
No known food interactions. No dietary restrictions required.
Pregnancy Category C. First trimester: potential for teratogenicity based on animal studies; avoid unless benefit outweighs risk. Second/third trimester: drug may cause fetal harm due to pharmacological effects; use only if clearly needed.
No evidence of teratogenicity; topical application with minimal systemic absorption. First trimester: unlikely risk. Second/third trimester: no known fetal risks from maternal use.
Excreted in human milk in unknown amounts; M/P ratio not established. Caution advised due to potential for serious adverse reactions in nursing infants; discontinue drug or nursing depending on importance to mother.
Minimal systemic absorption; unlikely to appear in breast milk. M/P ratio not established. Considered compatible with breastfeeding.
No established dose adjustments in pregnancy; pharmacokinetics may be altered due to increased plasma volume and metabolism. Use lowest effective dose; individualize therapy based on clinical response.
No dosage adjustment required; pharmacokinetics unlikely altered due to topical route.
AEROSEB-DEX is a fixed-dose combination of an inhaled corticosteroid (ciclesonide) and a long-acting beta-agonist (formoterol). Use as maintenance therapy for asthma, not for acute bronchospasm. Rinse mouth after inhalation to prevent oral candidiasis. Monitor for adrenal suppression with prolonged use. Dose formoterol component at low to moderate doses to minimize risk of asthma-related death.
ALA-SCALP is a topical aminolevulinic acid preparation used for photodynamic therapy of actinic keratoses on the scalp. Must be applied by a healthcare professional. Avoid sun exposure to treated area for 48 hours post-application due to photosensitivity. Do not apply to eyes or mucous membranes. Lesions should be prepped by gentle removal of scales and crusts. Use with a compatible light source (blue light). Burning and stinging during light exposure is common; consider pain management strategies.
Use regularly as prescribed, not for sudden breathing problems.,Rinse mouth with water after each use to prevent thrush.,Do not stop suddenly; taper under doctor guidance.,Seek emergency if rescue inhaler not effective.,Report worsening asthma, chest pain, or signs of steroid excess.
This medication is applied by your doctor to treat precancerous spots on your scalp.,After application, you will need a special light treatment (photodynamic therapy).,Avoid sunlight and bright indoor light on the treated area for 48 hours after the procedure.,You may experience temporary redness, swelling, scaling, or discomfort at the treatment site.,Use sunscreen and protective clothing when going outdoors during the photosensitivity period.,Do not wash the treated area for at least 4 hours after the solution is applied.,Contact your doctor if you experience severe pain, blistering, or signs of infection.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AEROSEB-DEX vs ALA-SCALP, answered by our medical review team.
AEROSEB-DEX is a Topical Corticosteroid that works by The combination product contains a corticosteroid (dexamethasone) which suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and a topical antibiotic (usually neomycin or polymyxin B) which inhibits bacterial protein synthesis or disrupts bacterial cell membranes.. ALA-SCALP is a Topical Corticosteroid that works by ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (Pp IX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), Pp IX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AEROSEB-DEX and ALA-SCALP depend on the specific clinical indication. These are both Topical Corticosteroid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AEROSEB-DEX is: 2 puffs (100 mcg each) intranasally twice daily. The standard adult dose of ALA-SCALP is: Topical application of a 5% solution to the scalp twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AEROSEB-DEX and ALA-SCALP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AEROSEB-DEX is classified as Category C. Pregnancy Category C. First trimester: potential for teratogenicity based on animal studies; avoid unless benefit outweighs risk. Second/third trimester: drug may cause fetal harm . ALA-SCALP is classified as Category C. No evidence of teratogenicity; topical application with minimal systemic absorption. First trimester: unlikely risk. Second/third trimester: no known fetal risks from maternal use.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.